Identification of personalized cancer neoantigens with HANSolo

IF 72.5 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2023-09-13 DOI:10.1038/s41568-023-00624-z

Chiara Maria Cattaneo

引用次数: 0

Abstract

In this Tools of the Trade article, Chiara Cattaneo describes the development of HANSolo, a high-throughput genetic platform for the personalized identification of CD4+ and CD8+ T cell-recognized (neo)antigens, that can be used to generate patient-specific TCR gene therapies or cancer vaccines.

查看原文本刊更多论文

用HANSolo鉴定个体化肿瘤新抗原。

在这篇 "贸易工具 "文章中，Chiara Cattaneo 介绍了 HANSolo 的开发情况，这是一个用于个性化识别 CD4+ 和 CD8+ T 细胞识别（新）抗原的高通量基因平台，可用于生成患者特异性 TCR 基因疗法或癌症疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.